CAS 85650-52-8|Mirtazapine
| Common Name | Mirtazapine | ||
|---|---|---|---|
| CAS Number | 85650-52-8 | Molecular Weight | 265.353 |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 432.4±45.0 °C at 760 mmHg |
| Molecular Formula | C17H19N3 | Melting Point | 114-116ºC |
| MSDS | ChineseUSA | Flash Point | 215.3±28.7 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | Mirtazapine |
|---|---|
| Synonym | More Synonyms |
Mirtazapine BiologicalActivity
| Description | Mirtazapine is a potent tetracyclic antidepressant.Target: 5-HT ReceptorMirtazapine, the novel antidepressant, has a dual mode of action. It is a noradrenergic and specific serotonergic antidepressant (NaSSA) that acts by antagonizing the adrenergic alpha2-autoreceptors and alpha2-heteroreceptors as well as by blocking 5-HT2 and 5-HT3 receptors [1].Mirtazapine appears to have a substantial ameliorating effect on hot flushes and perspiration bouts. It is postulated that the 5-HT(2A) blocking properties of mirtazapine is accounted in the symptomatic relief of hot flushes [2]. After 4-24 weeks of treatment, mirtazapine induced downregulation of platelet alpha(2A)-adrenoceptors (up to 34%) and Galphai proteins (up to 28%), and the upregulation of GRK 2 (up to 30%). Treatment with mirtazapine reversed this abnormality and induced downregulation of alpha(2A)-adrenoceptor/Galphai complex [3]. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>5-HT ReceptorSignaling Pathways >>Neuronal Signaling >>5-HT ReceptorResearch Areas >>Neurological Disease |
| References | [1]. Anttila, S.A. and E.V. Leinonen, A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev, 2001. 7(3): p. 249-64. [2]. Waldinger, M.D., H.H. Berendsen, and D.H. Schweitzer, Treatment of hot flushes with mirtazapine: four case reports. Maturitas, 2000. 36(3): p. 165-8. [3]. Garcia-Sevilla, J.A., et al., Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology, 2004. 29(3): p. 580-8. |
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 432.4±45.0 °C at 760 mmHg |
| Melting Point | 114-116ºC |
| Molecular Formula | C17H19N3 |
| Molecular Weight | 265.353 |
| Flash Point | 215.3±28.7 °C |
| Exact Mass | 265.157898 |
| PSA | 19.37000 |
| LogP | 2.75 |
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
| Index of Refraction | 1.668 |
| InChIKey | RONZAEMNMFQXRA-UHFFFAOYSA-N |
| SMILES | CN1CCN2c3ncccc3Cc3ccccc3C2C1 |
| Storage condition | Store at RT |
| Water Solubility | DMSO: ~8 mg/mL, soluble |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H336 |
| Precautionary Statements | P301 + P312 + P330 |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
| Hazard Codes | Xn |
| Risk Phrases | 22 |
| Safety Phrases | S22-S24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| HS Code | 2933990090 |
Customs
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Articles23
More Articles| Antidepressants activate the lysophosphatidic acid receptor LPA(1) to induce insulin-like growth factor-I receptor transactivation, stimulation of ERK1/2 signaling and cell proliferation in CHO-K1 fibroblasts. Biochem. Pharmacol. 95 , 311-23, (2015) Different lines of evidence indicate that the lysophosphatidic acid (LPA) receptor LPA1 is involved in neurogenesis, synaptic plasticity and anxiety-related behavior, but little is known on whether th... | |
| Simple and sensitive screening and quantitative determination of 88 psychoactive drugs and their metabolites in blood through LC–MS/MS: Application on postmortem samples J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 970 , 1-7, (2014) • The introduction has been modified. • More references have been added to the text. • Limitations of the method have been discussed more in detail. | |
| Analysis of drugs in plasma samples from schizophrenic patients by column-switching liquid chromatography-tandem mass spectrometry with organic-inorganic hybrid cyanopropyl monolithic column. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 993-994 , 26-35, (2015) This study reports on the development of a rapid, selective, and sensitive column-switching liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to analyze sixteen drugs (antidepressants, ... |
Synonyms
| Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl- |
| Zispin |
| (14bR)-2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine |
| 1,2,3,4,10,14B-HEXAHYDRO-2-METHYLPYRAZINO[2.1-A]PYRIDO[2.3-C][2]BENZAZEPINE |
| Mirtazapin |
| 1,2,3,4,10,14B-HEXAHYDRO-2-METHYLPYRAZINO[2,1-A]PYRIDO[2,3-C][2]BENZAZEPINE |
| Remeron |
| ORG-3770 |
| UNII:A051Q2099Q |
| 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine |
| MIRTAZEPINE |
| 2-Methyl-1,2,3,4,10,14b-hexahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepine |
| Mirtazanine |
| Avanza |
| MFCD00865427 |
| MIRTAZAPINE ANHYDRUOS |
| EINECS 288-060-6 |
